Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × OTHER × Birt-Hogg-Dube Syndrome × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 489 Colorectal Neoplasms 219 Neoplasms 208 Prostatic Neoplasms 191 Carcinoma, Non-Small-Cell Lung 169 Stomach Neoplasms 140 Carcinoma, Hepatocellular 136 Leukemia, Myeloid, Acute 130 Rectal Neoplasms 120 Multiple Myeloma 118 Lung Neoplasms 116 Nasopharyngeal Carcinoma 105 Colonic Neoplasms 96 Neoplasm Metastasis 91 Precursor Cell Lymphoblastic Leukemia-Lymphoma 79 Lymphoma 79 Pancreatic Neoplasms 76 Leukemia 72 Uterine Cervical Neoplasms 71 Lymphoma, Large B-Cell, Diffuse 69 Head and Neck Neoplasms 67 Brain Neoplasms 67 Lymphoma, Follicular 65 Esophageal Neoplasms 65 Ovarian Neoplasms 63 Recurrence 60 Squamous Cell Carcinoma of Head and Neck 51 Lymphoma, Non-Hodgkin 51 Leukemia, Lymphocytic, Chronic, B-Cell 51 Urinary Bladder Neoplasms 50

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00928798 2012-03-08

Topical Rapamycin for Fibrofolliculomas

Maastricht University Medical Center

Phase 3 Completed

Birt-Hogg-Dube Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡